Jefferies Financial Group started coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a report released on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.
Other equities research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. reaffirmed a sell rating and set a $18.00 price objective on shares of ABB in a research report on Monday. Roth Capital reaffirmed a buy rating on shares of Coeur Mining in a research report on Monday.
AKRO opened at $21.55 on Monday. Akero Therapeutics has a twelve month low of $16.06 and a twelve month high of $21.94.
In related news, Director Seth Loring Harrison bought 900,000 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was purchased at an average price of $16.00 per share, with a total value of $14,400,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio bought 250,000 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was bought at an average cost of $16.00 per share, with a total value of $4,000,000.00. The disclosure for this purchase can be found here.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
See Also: How is a Moving Average Calculated?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.